/ Print /

HOSPITAL & PROVIDER STRATEGY

Remote Patient Monitoring is a Wise Investment for PayersThe results of Geneia’s year-long study – a savings of $8,375 per patient and a slowing of disease progression – demonstrate that remote patient monitoring is a wise investment for payers.
Exchange plans are missing out on millions of dollarsA new Express Scripts report highlights risk reporting gaps and offers advice for plans looking to close those gaps to ensure accurate risk payments
Republicans face difficult post-election healthcare decisionsACA repeal/replace was a Congressional Republican cornerstone, so there will be lots of pressure to move quickly. But that may be easier said than done.
Non-physician providers play critical role in optimizing carePwC report finds most primary care teams not designed to optimize care. Here’s how to mobilize non-physicians to create a care dream team.
P4P programs feasible in addiction settingsAlcohol and drug dependency treatment goals can tied to an insurer’s pay-for-performance incentive program. Here’s how.
Are we relying too heavily on HCAHPS?How to really understand patient experience and improve outcomes. Here are five tips to help you create a culture of excellence.
AMA unveils tool to address ‘ever-widening gap’ in physician educationAs the industry moves toward value-based care, medical education must keep pace.
Six ways precision medicine is improving care
Six ways precision medicine is improving careHere are some of the latest precision medicine approaches being used by managed care organizations, health systems and academic medical centers across the U.S.
Top 10 states with the highest hospital safety scoresThe Leapfrog Group recently released its latest hospital safety grades, and they indicate some interesting trends on a state-by-state basis.
Cancer MoonShot 2020 will arm oncologists with new tools
Cancer MoonShot 2020 will arm oncologists with new toolsThe Cancer MoonShot 2020 program brings together stakeholders from pharma, community and academic oncology, as well as government and scientific communities in an effort to accelerate the potential of combination immunotherapy as the next-generation standard of care in cancer patients.